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Abstract 1 
Objective: The harmonization of core outcome domains in clinical trials facilitates 2 
comparison and pooling of data, and simplifies the preparation and review of 3 
research projects, and comparison of risks and benefits of treatments. Therefore we 4 
provide recommendations for the core outcome domains that should be considered in 5 
clinical trials on the efficacy and effectiveness of interventions for somatic symptom 6 
disorder, bodily distress disorder, and functional syndromes.  7 
Methods: The European Network on somatic symptom disorders group (EURONET-8 
Soma) of more than 20 experts in the field met twice in Hamburg to discuss issues of 9 
assessment and intervention research in somatic symptom disorder, bodily distress 10 
disorder, and functional syndromes. The consensus meetings identified core 11 
outcome domains that should be considered in clinical trials evaluating treatments for 12 
somatic symptom disorder and associated functional syndromes.  13 
Results : The following core domains should be considered when defining 14 
ascertainment methods in clinical trials: (1) classification of somatic symptom 15 
disorder/bodily distress disorder, associated functional syndromes, and comorbid 16 
mental disorders (using structured clinical interviews), duration of symptoms, medical 17 
morbidity, and prior treatments (2) location, intensity, and interference of somatic 18 
symptoms, (3) associated psychobehavioral features and biological markers, (4) 19 
illness consequences (quality of life, disability, health care utilization, health care 20 
costs ), (5) global improvement, treatment satisfaction, and (6) unwanted negative 21 
effects.  22 
Conclusions: The proposed criteria are intended to improve synergies of clinical trials 23 
and to facilitate decision making when comparing different treatment approaches. 24 
These recommendations should not result in inflexible guidelines, but increase 25 
consistency across investigations in this field.  26 
Words: 250 27 
Key Words: somatization, somatoform, bodily distress, functional somatic syndromes, 28 
fibromyalgia, irritable bowel syndrome. 29 
 30 
Abbreviations: 31 
BDD Bodily Distress Disorder 32 
BDS Bodily Distress Syndrome Checklist 33 
CIDI Composite International Diagnostic Interview 34 
DSM Diagnostic and Statistical Manual for Mental Disorders 35 
EMA Ecological Momentary Assessment 36 
3 
 
EuroQoL European Quality of Life Group 1 
HrQoL health related quality of life 2 
 3 
IBS: Irritable Bowel Syndrome 4 
 5 
IDCL International Diagnostic Check List 6 
 7 
NAS Numeric Analogue Scale 8 
 9 
IMMPACT Initiative on Methods, Measurement, and Pain Assessment in Clinical 10 
Trials 11 
 12 
PHQ Patient Health Questionnaire 13 
 14 
QALY: Quality adjusted Life years 15 
SCAN Schedules for Clinical Assessment in Neuropsychiatry 16 
 17 
SCID Structured Clinical Interview for DSM-IV/DSM-5 disorders 18 
SCL Symptom Check List 19 
SOMS-7 Screening for Somatoform Symptoms, last 7 days 20 
SSD Somatic Symptom Disorder 21 
SSD-12 Somatic Symptom Disorder Scale 22 
  23 
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Ascertainment methods, addressed domains and outcome reports in intervention 1 
trials on bodily distress disorder (BDD), somatic symptom disorder 2 
(SSD)/somatoform disorders and functional syndromes vary substantially. This has 3 
impeded evaluations of the efficacy and effectiveness of suggested treatment 4 
approaches. Current interventions on somatic symptom and associated disorders 5 
reveal moderate effect sizes for psychological interventions (1, 2), but also for 6 
pharmacological interventions like tricyclic antidepressants (3), which can be a result 7 
of moderately effective treatments, but also of flaws of assessment strategies. 8 
Agglomeration of results of intervention trials (e.g., in meta-analyses) is blurred by 9 
assessment tools that are not sufficiently evaluated about their sensitivity to assess 10 
change, by a large variability of assessment tools, by a lack of including relevant core 11 
domains for comparability, and other factors (2, 4). 12 
The development of a core set of outcome domains and quality criteria has been 13 
shown to improve comparison and pooling of data of intervention trials, while leaving 14 
investigators free to extend the core set with other instruments of their choice. In pain 15 
research, the introduction of the so-called IMMPACT criteria (5-7) led to a substantial 16 
improvement of the comparability and potential for accumulation of clinical trials. The 17 
introduction of quality criteria for intervention studies, such as the CONSORT criteria 18 
or the quality criteria of Cochrane analyses substantially improved the average 19 
quality of published clinical trials, and reduced the risk of publication of false-positive 20 
results. In the field of BDD, SSD and functional syndromes, the development of a 21 
recommended core set of outcome domains is still lacking, although assessment 22 
recommendations for single functional somatic syndromes have been published (e.g., 23 
for fibromyalgia (8)). Therefore the European Network on somatic symptom disorders 24 
(Euronet-SOMA) aimed to find a consensus for core domains to be assessed in the 25 
evaluation of interventions in the general field of somatic symptoms and associated 26 
disorders.  27 
 28 
Methods 29 
Two meetings of more than 20 European experts took place in Hamburg (Germany), 30 
and were organized by Bernd Löwe and his team in 2016. Several subgroups 31 
addressed different topics of research in somatic symptom disorder. Members of this 32 
subgroup were experienced in the conduct of clinical trials, and aggregation of 33 
different trial results. During the first session, we defined the clinical conditions of 34 
interest. After discussing different options, a consensus was reached to address 35 
somatic symptom disorder, bodily distress disorder, and associated functional 36 
syndromes. Reasons for this decision were the fact that these syndromes pretend to 37 
describe specific clinical conditions, although they are highly overlapping. The 38 
concept of somatic symptom disorder is defined in DSM-5; bodily distress disorder 39 
was originally defined by the Danish group of Per Fink, and it was shown that this 40 
definition covers most forms of somatization and functional somatic syndromes (9, 41 
10). For several functional somatic syndromes, current definitions and classification 42 
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criteria exist (e.g., ROME-III criteria for irritable bowel syndrome (11); fibromyalgia 1 
criteria (12)). To develop a consensus for assessment domains, we analyzed the 2 
IMMPACT criteria, results of Cochrane and other meta-analyses in the field of SSD 3 
or BDD, recommendations for outcome measurement in specific syndromes, such as 4 
irritable bowel syndrome and fibromyalgia, general recommendations about the 5 
assessment of change in psychosomatic, psychiatric and psychological research, as 6 
well as specific results on the quality of assessing change of various assessment 7 
tools (e.g.,(13)).All participants of this specific working group were invited to name 8 
existing recommendations for outcome measurements of the corresponding groups. 9 
These nominations were collected and grouped to domains. The resulting proposal of 10 
domains was presented during the second meeting, and further discussed. These 11 
discussions led to further adaptations. After the second meeting, the resulting 12 
proposal was circulated twice to find a general agreement. Afterwards, this 13 
agreement was further circulated to the overall group, and finally harmonized. The 14 
final proposal was accepted by all group members. Of note, while recommendations 15 
for the assessment of trait variables and current state variables of somatic symptoms 16 
in particular for epidemiological research have been published elsewhere (4), more 17 
specific challenges of selecting tools for the assessment of change are addressed in 18 
this paper.  19 
 20 
Results 21 
All clinical trials of this field should consider reporting in agreement with the general 22 
quality criteria for clinical trials, such as the CONSORT criteria, with their specific 23 
recommendations. In particular, the description of interventions, the selection of 24 
participants, inclusion and exclusion criteria, the definition of concurrent treatments, 25 
the assessment of treatments during follow-up periods, randomization and blinding 26 
procedures, statistical management of missing values and drop-outs, adherence to 27 
treatment guidelines etc. are crucial pre-requisites to evaluate scientific rigor and 28 
clinical implications of these trials.  29 
 30 
The CONSORT criteria suggest defining specific primary outcome variables. In 31 
addition to identifying the primary outcome of a trial, present recommendations add a 32 
broad variety of assessment domains relevant to SSRD/BDD, to facilitate the 33 
comparison and agglomeration of different clinical intervention effects. To accomplish 34 
this goal, we had to consider the broad variety of diagnoses, concepts, and 35 
approaches of this clinical group. We recommend the following domains to be 36 
addressed in clinical trials (for an overview see Table 1): 37 
(1) Classification of disorder, comorbid mental and physical conditions 38 
In a field where differing terminologies and classifications have all too often 39 
hampered transparency and comparability, a clear definition of the disorder in 40 
question and its comorbid aspects is of prime importance. While DSM-5 and/or 41 
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ICD-11 diagnoses should be adequately addressed, broader and/or additional 1 
ways of classification can be useful considering the limited duration of validity of 2 
current classification systems. For the purpose of classification, structured clinical 3 
interviews are the current gold standard of assessments in particular for mental 4 
disorders. Various evaluated methods exist with specific strength and limitations, 5 
such as the structured clinical interview for DSM classification SCID (14), the 6 
Composite International Diagnostic Interview (CIDI) (15), the Schedules for 7 
Clinical Assessment in Neuropsychiatry (SCAN) (16), among other interviews. A 8 
semi-structured approach such as the International Diagnostic Check Lists (IDCL) 9 
(17) can offer an economic alternative. In any case, a clear description of the 10 
selected sample and consideration of inclusion and exclusion criteria requires the 11 
use of one of these types of instruments. While a clear description of inclusion 12 
criteria is a prerequisite of high quality trials, investigators should be aware of the 13 
tremendous overlap of symptom profiles and other characteristics of functional 14 
somatic syndromes (10, 18). Therefore it is crucial to use broad-spectrum 15 
assessments for multiple symptoms or multi-symptomatic syndromes in addition 16 
to focusing on any particular symptom profile. Symptom onset, symptom duration, 17 
and treatment pre-experiences should be additionally investigated. A re-18 
assessment at end-of-treatment and/or follow-up is strongly recommended. In 19 
combination with potential expert disability ratings (see below), these ratings 20 
should be done by raters blinded to the treatment selected for this patient - this 21 
could lead to expert ratings of remission and response rates.  22 
The diagnosis of Somatic Symptom Disorder according to DSM-5 as well as the 23 
current ICD-11 proposal of Bodily Distress Disorder do not exclude the existence 24 
of comorbid medical conditions. SSD can be used as a diagnosis even if all 25 
somatic symptoms are explained on the background of a medical disease, such 26 
as cancer, because for the SSD diagnosis the burden of the symptoms is more 27 
relevant than the postulated etiology. Several functional somatic syndromes 28 
require that their core symptoms (e.g. abdominal pain in case of irritable bowel 29 
syndrome) are not mainly explained by a general medical disease. Nevertheless, 30 
also these functional syndromes often co-occur with physical diseases. Moreover, 31 
co-occurring medical conditions influence other relevant clinical outcome 32 
measures and health care use (19) Therefore it is crucial to assess the co-33 
occurrence of physical diseases carefully. Binary checklists for somatic illnesses, 34 
such as the WHO checklist of chronic diseases in the SCAN (16) help to ensure 35 
that a comprehensive description of the somatic and psychological dimensions of 36 
the patient’s medical status is given. In more severely affected or inpatient 37 
samples, the updated Charlson comorbidity index could also be relevant (20). 38 
Depending on the research question, repeated measurement could be useful. 39 
 40 
 41 
(2) Assessment of somatic symptoms 42 
While DSM-5 has shifted the focus of classification from the assessment of 43 
somatic symptoms to the consideration of concurrent psychosocial factors, clinical 44 
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trials should continue to assess the different facets of somatic symptoms (e.g., 1 
multiplicity of symptoms, location and type of symptoms, intensity, occurrence, 2 
duration, interference with daily activities) as change in symptoms will continue to 3 
be a central outcome feature of treatments for patients and physicians/ therapists 4 
alike. Although more sophisticating assessment tools are additionally necessary, 5 
we recommend the use of two numerical rating scales (NRS; see Table 2) to 6 
assess  7 
x Symptom intensity 8 
x Symptom interference with daily activities 9 
 10 
The field of pain research has strongly benefited from using these two simple to 11 
use NRS. It allows comparing the efficiency of interventions between clinical trials. 12 
NRS have been shown to be sensitive to the assessment of change, valid, and 13 
simple to use (21) . A commonly used time frame for assessing somatic 14 
symptoms with a NRS is 7 days. 15 
Self-rating scales should be used that are specifically evaluated to assess 16 
changes of somatic symptoms. While the Patient Health Questionnaire PHQ-15 is 17 
one of the most frequently used instruments to identify people at risk for 18 
somatization, its sensitivity to assess change was only sparsely evaluated (22). 19 
However, it has shown treatment effects in some evaluation trials (e.g., (23)). The 20 
somatization subscale of the Symptom Checklist SCL-90R is also frequently 21 
used, albeit its specificity for somatic symptom disorder is less clear (24). The 22 
Screening for Somatoform Symptoms (SOMS-7) has been evaluated for the 23 
sensitivity to assess change (25), but represents a very broad assessment tool. 24 
The Bradford Somatic Inventory (BSI) claims to be valid for multiple ethnic groups 25 
(26), which is an aspect that was frequently neglected during assessment tool 26 
evaluation. The Bodily Distress Syndrome Checklist (BDS) has been validated as 27 
a screening tool for bodily distress syndrome (27), but its sensitivity to assess 28 
change needs further evaluation.  29 
In contrast to pain research, symptom diaries and other experience sampling 30 
methods are less frequently used in the field of SSD or BDD. However, they could 31 
provide information that goes far beyond self-rating scales, and new technologies 32 
are further facilitating their application (28)(e.g., ecological momentary 33 
assessments EMA). Multiple assessments allow the analysis of patterns of 34 
change, and the use of time-lag analyses. If diaries are used, it is recommended 35 
not only to use “negative” items (e.g., current symptom intensity), but also to 36 
address positive features (e.g., current ability to cope with symptoms, current 37 
ability to enjoy life despite of symptoms) (29).  38 
 39 
(3) Psychobehavioral features 40 
DSM-5 introduced classification-relevant psychobehavioral features of SSD, such 41 
as health anxiety, illness worry, excessive time and energy spent on the 42 
symptoms or health concerns. Therefore these features are part of the 43 
classification process (domain #1), but often they also determine significant parts 44 
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of the overall suffering of patients, and they also belong to potential mechanisms 1 
of symptom development and symptom maintenance. Therefore they also 2 
constitute a core outcome domain. Several assessment tools have been 3 
developed to investigate these features. The frequently used Whiteley-Index WI is 4 
a well-established and economic instrument to assess health anxiety (30), but 5 
also other instruments have demonstrated sensitivity to assess change in this 6 
field (31). New developments try to cover the full spectrum of the B-criteria of 7 
somatic symptom disorder (i.e., the cognitive, affective and behavioral impact of 8 
symptoms), e.g. the Somatic Symptom Disorder Scale (SSD-12) (32). Again, their 9 
sensitivity to assess change has to be further evaluated. 10 
Anxiety and depression are frequently co-occurring psychopathological 11 
phenomena. Therefore the assessment of broader psychopathology beyond 12 
somatization is strongly recommended. Typical assessment tools are the SCL-13 
90R, the anxiety and depression subscales of the Patient Health Questionnaire 14 
PHQ (33-35), or other self- and expert ratings on psychopathology (36, 37)  15 
The assessment of psychological features of the disorders should also 16 
address potential mechanisms of change/mediators. Somatosensory amplification 17 
(38) describes the vicious circle of illness anxieties, attention focusing, and 18 
amplified perception of symptoms, and catastrophizing of symptoms (39). This 19 
mechanism shows close relationships with bodily vigilance (40). Fear avoidance 20 
has been shown to be one of the most powerful predictors of the development of 21 
symptom persistence/chronicity (41), and it is considered to be a major 22 
maintaining factor for these types of symptoms (42). Patients can show 23 
dysfunctional illness behavior that contributes to the maintenance of symptoms. 24 
Many interventions try to improve symptom coping skills, and reduction in fear 25 
avoidance or symptom catastrophizing partially mediates treatment effects across 26 
various syndromes (43, 44). These variables should be addressed accordingly. 27 
Illness beliefs in general, such as assumptions about the etiology of symptoms, 28 
suspected medical explanations, expected course and treatment responses are 29 
examples of components of illness beliefs. Some of these components can be 30 
dysfunctional (e.g. in contributing to high health expenditures (45)), and need to 31 
be changed during interventions. A typical instrument to assess these illness 32 
beliefs is the Illness Perception Questionnaire (46), which is also available in a 33 
shortened version (47). However, depending on the rationale of the treatment 34 
approach, other mechanisms of change can be postulated, and should be 35 
assessed accordingly (e.g., emotion regulation, attachment insecurity (48), 36 
reduction of avoidance behavior, reduction of symptom reinforcement via 37 
relatives, increase of acceptance and mindfulness, and communication skills). 38 
The assessment of mediators could be complemented with the evaluation of 39 
potential moderators (e.g., personality traits such as neuroticism or negative 40 
affectivity, gender, age).  41 
 42 
(4) Illness consequences (Qualtiy of life and disability assessment) 43 
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Health related quality of life (HrQoL) is the most relevant outcome domain in this 1 
field, and its assessment should address issues such as physical functioning, 2 
psychological and emotional functioning, but also functioning in social roles. The 3 
most frequently used assessment tool for HrQoL is the Short Form SF-36 or its 4 
abbreviated version SF-12 (49, 50). This has been specifically adapted for the use 5 
in the field of SSD (51). As an alternative or extension to the assessment of 6 
HrQoL, assessments of disability are highly recommended. A frequently used 7 
assessment tool that is both economic and valid to assess change is the Pain 8 
Disability Inventory, which has been adapted to somatic symptoms in general 9 
(52). Also frequently used are the Sheehan Disability Scales (53). Finally, health 10 
care costs and health care utilization are considered to be of pivotal relevance in 11 
somatization syndromes, in particular because a substantial subgroup of patients 12 
is characterized by continuous health-care seeking. Although variables of health 13 
care use and costs are notoriously associated with statistical distribution and 14 
evaluation problems, their financial relevance should motivate to address this 15 
issue in clinical trials. In combination with health economic research questions, 16 
the assessment of quality-adjusted life years (QALY) is needed. For this purpose 17 
instruments such as the EuroQol (EQ-5D; (54)) or the SF-6D (55) can be used as 18 
an alternative to the SF-36. Recently, the reQOL has been developed which has 19 
been validated to give a better assessment of QOL in mental disorders 20 
(www.reqol.org.uk/p/overview.html). 21 
 22 
(5) Consumer satisfaction 23 
A global rating on treatment success from the perspective of the patient is also 24 
highly recommended. It is obvious that the definition of improvement by a patient 25 
can substantially differ from the improvements shown in symptom scales, or as 26 
evaluated via clinical expert ratings. Additionally, treatment satisfaction can also 27 
represent a variable that is of substantial relevance, but not identical to other 28 
suggested variables. The “recommendation item” (“Would you recommend this 29 
treatment to another person/a friend with similar problems?”) is one possible 30 
simple item that could be used in all clinical trials to assess treatment satisfaction. 31 
Consumer satisfaction scales have been developed for other clinical fields (56), 32 
but can be easily adapted to the focus group of this manuscript. 33 
The effect of psychological interventions strongly depends on factors such as 34 
credibility of treatment, therapeutic relationship, and expectation of improvement. 35 
Therefore their assessment is recommended if psychological interventions are 36 
compared and evaluated. A brief scale to address these topics has been 37 
suggested (57). For the assessment of the quality of the therapeutic relationship, 38 
several screeners have been published (e.g. (58, 59)).  39 
 40 
(6) Unwanted negative treatment effects 41 
A scientifically-based treatment recommendation requires an evaluation of the 42 
expected positive treatment effects in relation to potential negative outcomes. 43 
However, even in pharmacology research, side effects are frequently assessed 44 
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with unsatisfactory methods (60, 61). Over the last century, psychotherapy 1 
research has also neglected the issue of unwanted negative effects (62). 2 
However, considering the vulnerable states of many patients with SSD/BDD as 3 
well as the many problematic experiences that patients report from past 4 
treatments, it is strongly recommended to assess unwanted negative effects 5 
during and after treatment. It is not considered sufficient just to add one or two 6 
open questions, and to rate their answers by experts about their relevance, as 7 
was frequently done in pharmacology research (63). More systematic 8 
assessments for negative effects are required both in psychological intervention 9 
trials and pharmacological intervention trials; just recently, assessment tools to 10 
ascertain negative effects of psychotherapy have been developed, although this 11 
field is just at the beginning of validating corresponding instruments (64, 65). In 12 
pharmacological trials, systematic and structured assessments should 13 
complement registrations that are more spontaneous and observation-based (65, 14 
66). 15 
 16 
Discussion 17 
In this manuscript, we present consensus recommendations on which domains 18 
should be covered when planning the assessment tools in clinical trials in the field of 19 
SSD, BDD, and functional syndromes. While such a multidimensional approach 20 
should not replace other quality criteria of clinical trials (such as the definition of 21 
primary outcome variables), it should facilitate the comparability between clinical 22 
trials and help optimize the accumulation of results from different trials, e.g. in meta-23 
analyses or Cochrane analyses.  24 
A harmonization of assessments between clinical trials has the potential to not only 25 
substantially improve trial quality per se, but also the synergistic potentials between 26 
trials. It would be extremely helpful to have at least one or two very simple 27 
assessment methods that should be part of most clinical trials such as two suggested 28 
NRS on symptom intensity and interference with daily activities respectively (domain 29 
#2). Moreover, the definition of domains should also help to decrease the notorious 30 
lack of information, as soon as other than the primary variables are analyzed in meta-31 
analyses. When features such as comorbid emotional problems, psychobehavioral 32 
features (domain #3) and illness consequences (quality of life and disability ; domain 33 
#4) are subject of agglomeration of trials, often less than 30% of the original trials 34 
provide full data (1). In such a situation, where the majority of published trials cannot 35 
be used, scientific and clinical progress will be unnecessarily delayed, and most 36 
conclusions from clinical trials must remain incomplete.. Moreover, a systematic 37 
consideration of potential mediators and moderators of interventions offers a basis for 38 
targeted treatment decisions. Therefore we expect a major breakthrough if these 39 
recommendations are considered in future clinical trials.  40 
11 
 
While the IMMPACT criteria and CONSORT criteria offer stimulating and thoughtful 1 
recommendations, a specific adaptation to the field of SSD, BDD, and functional 2 
syndromes is necessary. CONSORT offers a general quality framework for all clinical 3 
trials, which needed to be more specified for the field of interest of this paper. 4 
Specific domains of necessary ascertainments beyond the definition of primary, 5 
secondary outcome variables, and side effects are not specified in CONSORT 6 
criteria, but in our paper. IMMPACT has a strong focus on specific pain syndromes. 7 
While pain syndromes are also of relevance for many functional syndromes, the 8 
scope has to be broadened up for SSD, BDD and functional syndromes, to address 9 
the multiplicity of symptoms, the large overlap between different functional 10 
syndromes, and considering that for some functional syndromes, non-pain symptoms 11 
are crucial (e.g., chronic fatigue). Therefore, not surprisingly, some recommendations 12 
of our approach show similarity to IMMPACT recommendations (e.g., physical and 13 
emotional functioning; participant ratings of improvement and satisfaction with 14 
treatment; symptoms and adverse events), while others are adapted to the field of 15 
interest (e.g., classification issues; how to address somatic conditions; addressing 16 
overlap between functional syndromes; distinction between illness consequences 17 
and psychobehavioral mechanisms). 18 
 19 
Another advantage of these recommendations is the inclusion of frequently 20 
neglected, yet highly relevant variables. The neglect of assessing unexpected 21 
negative effects in clinical trials investigating psychological interventions is one of the 22 
most impressive examples of blind spots in clinical research. However, if 23 
interventions increase the risk of somatic symptom turbulences, emotional crisis, 24 
suicidal ideation, or if patients feel that they are not taken seriously, such an 25 
intervention should be considered more critically compared to other interventions with 26 
similar benefits, but fewer of these negative effects. Therefore an adequate benefit-27 
risk-evaluation requires not only the assessment of treatment advantages, but also of 28 
treatment-related problems (domain #5). These unwanted treatment outcomes may 29 
also influence patients’ consumer satisfaction of the intervention, which is another 30 
important outcome (domain #6)..  31 
When summarizing these recommendations, it also became evident that cultural 32 
adaptations of instruments are mostly lacking. This is all the more problematic, as 33 
somatic symptoms are embedded and experienced in the context of culture and 34 
language and thus differ in terms of type, location, intensity and ways of 35 
communicating them.  Most intervention trials included patients with diverse 36 
backgrounds, and these effects of diversity can further add to uncontrolled variance if 37 
instruments are used without cultural equivalence or adaptation. 38 
Publishing recommendations always bears the risk of over-standardization, while 39 
research progress needs some competition between conflicting approaches. Our aim 40 
is to provide a set of domains which are advantageous to address, rather than setting 41 
strict standards for future trials. Although we mention several specific assessment 42 
tools, this is only done to highlight examples for the field, while the genuine 43 
12 
 
recommendations primarily cover the six core domains. It remains up to the 1 
investigators to select assessment tools for these domains, but also to extend the 2 
suggested domains with other fields of interest. However, we want to encourage the 3 
use of multi-methodological approaches: the use of expert ratings can easily lead to 4 
over-estimations of intervention effects, and should always be complemented with 5 
validated self-ratings focusing on patient’s perspective (67, 68). 6 
Moreover we want to emphasize that in addition to statistical significance also clinical 7 
significance should be considered. Clinical significance accounts for the clinical 8 
relevance of individual patient’s response to a treatment. There are many different 9 
methods of analyzing clinical relevance. For continuous data the reliable change 10 
index has been recommended since it incorporates the standard error of the 11 
measurement depending on the measurement’s reliability . However the cut-off of the 12 
RCI>1.96 indicating reliable change is not feasible for the assessment of change of 13 
somatic symptom intensity, and is highly dependent on the variability of the 14 
assessment tool as well as the correlation of the assessment tool over repeated 15 
measures. For dichotomous data the number needed to treat for another beneficial 16 
outcome (NNTB) is often used which is defined as the number of participants that 17 
needed to be treated for one to benefit in a given time frame. Since clinical 18 
significance regarding the outcome domains has not been examined sufficiently for 19 
our field, empirical criteria of clinically significant change cannot be provided. We 20 
refer to a recommendation by the Initiative on Methods, Measurement, and Pain 21 
Assessment in Clinical Trials (IMMPACT) which provides provisional criteria for 22 
interpreting the clinical importance of treatment outcomes in clinical trials of patients 23 
with chronic pain (69). For example, a decrease of 30% on a 0-10 NRS measuring 24 
pain intensity was defined as a moderately important change, and a decrease of 25 
DVDVXEVWDQWLDOLPSURYHPHQW The proposed multi-domain assessments will 26 
enable investigation of whether such improvements are paralleled by changes in 27 
other domains relevant to SSD, BDD and functional symptom disorders. 28 
For the evaluation of clinical trials, there is no need to show improvements on all 29 
recommended domains for a single intervention, and in most cases it will be essential 30 
to establish an a priori primary outcome measure. However, it is important to realize 31 
that treatment effects can differ substantially between the specific domains. 32 
Treatments can substantially improve quality of life, although not change symptom 33 
intensity (e.g., if the focus is on acceptance strategies). The relevance of specific 34 
core domains can also vary depending on selection criteria and aim of the study: if, 35 
for instance, patients with abnormal health care use are selected for treatments, the 36 
effects on health care utilization can be of more relevance than the effect on 37 
comorbid emotional problems. Moreover, the relevance of each domain  partially 38 
depends on one’s theoretical perspective or clinical interest. For referring physicians, 39 
the improvement of symptoms could be of major interest, whereas the reduction of 40 
health care utilization could be more relevant for health care insurances. Similarly, 41 
working ability and role functioning are crucial from a societal perspective; and for the 42 
patient and significant others issues related to life satisfaction are likely to be 43 
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essential treatment outcomes. These examples highlight that the recommended core 1 
domains reveal relevant and necessary information to evaluate a specific treatment 2 
of interest in comparison to other treatments, and to reveal the relevant information 3 
for the specific interest group.  4 
While the IMMPACt criteria of pain research stimulated the development of the 5 
EuronetSOMA criteria, the later ones try to extend this proposal, and to tailor it 6 
specifically to the field of somatic symptom disorder, bodily distress disorder, and 7 
functional syndromes. Specific recommendations are included how to address the 8 
diversity of included syndromes, how to address comorbid medical conditions, or how 9 
to assess unwanted negative effects of interventions. Beyond these more specific 10 
recommendations, the attempt to harmonize domains of evaluation methods is 11 
expected to accelerate progress of intervention research in this field. Therefore, we 12 
anticipate that the  recommendations of core domains for outcome assessment in 13 
clinical trials of somatic symptom disorder will result in more consistency in trial 14 
design and output assessment with the goal of improving interpretability and 15 
generalizabilityof clinical trials in this field. 16 
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Table 1: Overview on core domains to assess change in clinical trials on somatic 1 
symptom and associated disorders 2 
Domain 
 
Specifications 
Classification of disorder and comorbid mental 
problems 
Validated structured clinical 
interview including specific 
criteria for the most important 
associated syndromes 
(fibromyalgia, irritable bowel 
syndrome, chronic fatigue 
syndrome, etc.). Duration/onset 
of symptoms. Pre-treatments. 
Assessment of somatic symptoms 2 NRS (0..10; see Table 2):  
- Symptom Intensity 
- Symptom Interference 
 
Self-rating symptom scales, 
Symptom diaries, EMA 
Psychobehavioral features  B-criteria of DSM-5 
Psychopathology (Depression, 
Anxiety) 
Potential mechanisms (health 
anxiety, psychobiological 
markers, a.o.) 
Illness consequences Quality of Life; disability 
Health care use 
Consumer satisfaction Treatment satisfaction; 
recommendation item; 
Therapeutic relationship; 
Expectations 
Unwanted negative effects Worsening of problems 
Unexpected new problems and 
symptoms 
Systematic side effects 
assessements 
 3 
  4 
19 
 
Table 2 1 
Recommendations for 2 Numeric Analogue Scale Items to Be Used in Clinical 2 
Trials 3 
 4 
Symptom Intensity: 5 
During the last 7 days, the overall intensity of my bodily symptoms was: 6 
No Symptoms at all      Worst possible symptoms 7 
 8 
0           10 9 
 10 
 11 
Symptom Interference: 12 
During the last 7 days, my bodily symptoms interfered with daily life activities 13 
Not at all       Interfered completely 14 
 15 
0           10 16 
 17 
  18 
20 
 
Appendix 1 
Recommendations for 2 Numeric Analogue Scale: Non-English examples 2 
 3 
German: 4 
* Symptom Stärke: Während der letzten 7 Tage war die Gesamtstärke meiner 5 
körperlichen Beschwerden: 0 = überhaupt keine Beschwerden – 10 = 6 
schlimmstmögliche Beschwerden 7 
* Symptom Beeinträchtigung: Während der letzten 7 Tage haben mich meine 8 
körperlichen Beschwerden bei Alltagsaktivitäten beeinträchtigt: 0 = überhaupt nicht – 9 
10 = extrem beeinträchtigt 10 
 11 
Danish 12 
*Symptomernes intensitet: Hvor intense har mine fysiske symptomer været i de 13 
sidste 7 dage?: 0 = slet ingen symptomer – 10 = værst mulige symptomer 14 
*Symptomernes påvirkning: Hvor meget har mine fysiske symptomer påvirket  mine 15 
dagligdags aktiviteter i de sidste 7 dage?: 0 = slet ikke påvirket – 10 = påvirket 16 
ekstremt meget 17 
 18 
Dutch 19 
*Intensiteit van symptomen: Gedurende de afgelopen 7 dagen was de globale 20 
intensiteit van mijn lichamelijke symptomen: 0 = helemaal geen symptomen – 10 = 21 
meest erge symptomen 22 
 23 
*Belemmering door pijn: Gedurende de afgelopen 7 dagen hebben de lichamelijke 24 
symptomen mij belemmerd in mijn dagelijkse activiteiten: 0 = helemaal niet – 10 = 25 
volledige belemmering  26 
 27 
French 28 
*Intensité des symptoms: Pendant les 7 derniers jours, l'intensité globale de mes 29 
symptômes physiques était: 0 = pas des symptômes du tout – 10 = intensité des 30 
symptômes totales 31 
 32 
*Interférence par symptoms: Pendant les 7 derniers jours, mes symptômes 33 
physiques interféraient avec mes activités journalieres: 0 = pas d'interférence du tout 34 
- 10 = interférence totale 35 
 36 
Lithuanian 37 
6LPSWRPXLQWHQVLWƗWH 3ƝGƝMRGLHQXODLNƗPDQXƷHUPHƼDVLPSWRPXLQWHQVLWƗWHELMD38 
 QHELMDQHNƗGXVLPSWRPX– 10 = vLVOLHOƗNƗLQWHQVLWƗWƝ 39 
*6LPSWRPXPLMLHGDUEƯED 3ƝGƝMRGLHQXODLNƗPDQLƷHUPHƼDVLPSWRPLWUDXFƝMD40 
GLHQDVDNWLYLWƗWƝV QHPD]– 10 = vLVOLHOƗNƗPƝUƗ 41 
 42 
Norwegian 43 
*Symptomenes intensitet: I løpet av de siste 7 dagene har intensiteten av mine 44 
kroppslige symptomer vært: 0 = ingen symptomer i det hele tatt – 10 = verst mulige 45 
symptomer 46 
*Symptomenes påvirkning: I løpet av de siste 7 dagene har mine kroppslige 47 
symptomer påvirket mine daglige aktiviteter: 0 = ikke det det hele tatt – 10 = påvirket 48 
disse fullstendig 49 
 50 
Russian 51 
21 
 
*ɂɧɬɟɧɫɢɜɧɨɫɬɶɫɢɦɩɬɨɦɚȼɬɟɱɟɧɢɟɩɨɫɥɟɞɧɢɯɞɧɟɣɨɛɳɚɹɢɧɬɟɧɫɢɜɧɨɫɬɶ1 
ɦɨɢɯɬɟɥɟɫɧɵɯɫɢɦɩɬɨɦɨɜɛɵɥɚɫɥɟɞɭɸɳɟɣ 0 = Ɉɬɫɭɬɫɬɜɢɟɫɢɦɩɬɨɦɨɜ – 10 = 2 
Ɇɚɤɫɢɦɚɥɶɧɚɹɜɵɪɚɠɟɧɧɨɫɬɶɫɢɦɩɬɨɦɨɜ 3 
*Ɉɝɪɚɧɢɱɟɧɢɹ ɜɫɥɟɞɫɬɜɢɟɫɢɦɩɬɨɦɚȼɦɟɲɚɬɟɥɶɫɬɜɨɫɢɦɩɬɨɦɚ: ɇɚɫɤɨɥɶɤɨ4 
ɫɢɥɶɧɨɜ ɬɟɱɟɧɢɟɩɨɫɥɟɞɧɢɯɞɧɟɣɦɨɢɬɟɥɟɫɧɵɟɫɢɦɩɬɨɦɵɦɟɲɚɥɢɦɨɟɣ5 
ɩɨɜɫɟɞɧɟɜɧɨɣɠɢɡɧɟɞɟɹɬɟɥɶɧɨɫɬɢ: 0 = ɋɨɜɫɟɦɧɟɦɟɲɚɥɢ – 10 = ɦɟɲɚɥɢ6 
ɩɨɫɬɨɹɧɧɨ 7 
 8 
 9 
 10 
